Key words: HBV, Taiwan, epidemiology, vaccination program, hepatitis B vaccine
|
|
- Jeffry Morrison
- 5 years ago
- Views:
Transcription
1 Original Article 521 Forecasting the Declining Rate of Chronic Hepatitis- Carrier Status at a Taiwanese University: Twenty Years after Implementation of an Universal HV Vaccination Program in Taiwan Fu-Hsiung Su, MS; Hsiao-Yun Huang 1, PhD; Hong-Jer Chang 3, PhD; Jin-Ju Jeng 2, S; Yi- Hui Liu 3, A; Chih-Dao Chen, MD ackground: Prior to the introduction of universal hepatitis virus (HV) vaccination in Taiwan in 1984, 15-20% of the general population were chronic HV carriers. Methods: We forecasted and quantified the declining HV carrier rate 20 years subsequent to the implementation of universal HV vaccination in Taiwan. At a Taiwanese university, 28,763 freshmen tested for serum HsAg level were divided into ten age cohorts by date of birth, from July 1976 to June 1986 inclusive. Comparisons of HsAg carrier rates according to gender were examined with the Z test. Regression methods and a time series model were applied to our sample to forecast trends in changes to the HsAg carrier rate Results: for the next five years. Regression analysis demonstrated a trend toward declining HsAg-positive carrier rates. The HsAg carrier rate for male students decreased from 16.8% (for those born between July 1976 and June 1977) to 2.2% (for those born between July 1985 and June 1986). The carrier rate for their female counterparts over the same period declined from 12.2% to 2.4%. The HsAg carrier rate for male participants was significantly greater than that of their female counterparts for certain years during the test period. The results of time series analysis suggests the HsAg carrier status rate will approach zero for students born after July 1987 (expected to enrol in the university in 2006). Conclusions: Our data demonstrate that in order for the HV carrier rate to approximate zero, universal vaccination programs need to continue for at least 21 years. (Chang Gung Med J 2007;30:521-8) Key words: HV, Taiwan, epidemiology, vaccination program, hepatitis vaccine Hepatitis- infection, a global health issue, is particularly prevalent in developing countries. ased on serological evidence, it has been estimated that each year, approximately two billion individuals From the Department of Family Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan; 1 Department of Statistics and Information Science; 2 Student Health Center, Fu Jen Catholic University, Taipei, Taiwan; 3 Institute of Long-Term Care, National Taipei College of Nursing, Taipei, Taiwan. Received: Aug. 2, 2006; Accepted: Mar. 23, 2007 Correspondence to: Dr. Chih-Dao Chen, Department of Family Medicine, Far Eastern Memorial Hospital. 21, Sec. 2, Nanya S. Rd., anciao City, Taipei County 220, Taiwan (R.O.C.) Tel.: ext. 4206; Fax: ; cdchen@mail.femh.org.tw
2 Fu-Hsiung Su, et al Forecasting HV rate at a college in Taiwan 522 worldwide succumb to hepatitis- infections they contracted in the past. (1) Of these, perhaps 350 million appear to be chronic carriers, of whom possibly one million die annually from cirrhosis and/or hepatocellular carcinoma. (2) Listed among the hyperendemic countries, Taiwan appears quite significant in that it features one of the highest HsAg carrier rates in the world, with perhaps 15 to 20% of the general population being carriers. (3-5) In 1984 Taiwan became one of the first countries to implement an universal hepatitis- vaccination program for newborns. (6,7) Vaccination for newborns of carrier mothers was implemented in July 1984 and was extended to include all neonates in The program reached somewhere between 84 and 94 percent of the population. At the commencement of the vaccination program, the HV carrier rate among children was 9.8 percent. (6) Five years later, the HsAg seropositivity rate for children under five years of age had decreased to 2%. (8) After ten years (1994), the HV carrier rate among children had decreased to 1.3 percent. (6,9) After sixteen years (the year 2000), a significant trend toward decreasing HsAg carrier rates-from 20.3% (those born in 1976) to 3.4% (born in 1986)-was reported for high-school students in eastern Taiwan. (10) Such studies show the HV infection and carrier rates have been declining since the launch of this mass vaccination program, (6,7) although the long-term efficacy of a mass HV vaccination program such as this remains a question of great concern for publichealth officials. In this article, we report HV infection trends for ten birth cohorts of Taiwanese university students, for the decades prior and subsequent to 1984, the year when Taiwan s national hepatitis- vaccination campaign for neonates commenced. The results of this study confirm that the effect remained significant 20 years after the first cohort received HV vaccinations, which were ongoing thereafter. Furthermore, we observe that unvaccinated children have also benefited from the hepatitis- vaccination program. METHODS National vaccination program Taiwan s nationwide program of HV vaccination started in July 1984 and for the first two years of the program, only newborns of HsAg-positive mothers were immunized. From July 1986 onwards, all infants were immunized. The program was extended to preschool children in , to primary school children in , to teenagers in , and to adults in on a fee-forservice basis. eginning in October 1990, the freeof-charge H vaccination program was expanded to include all children up to first grade. Since July 1991, the vaccine records of elementary-school entrants have been checked to confirm H vaccination, and non- or incompletely vaccinated elementary school students have been monitored and given a full-cycle of catch-up vaccinations. Participants The study data were collected from Fu-Jen Catholic University, a private university located in northern Taiwan. Using birth place information available in university records, it was determined that the majority (72.6%) of the students in the study were from northern Taiwan (including 59.3% from the Greater Taipei Metropolitan Area) with only 13.2% from central Taiwan, 10.8% from southern Taiwan, and 3.4% from eastern Taiwan and the outlying islands. According to the university s policy, all students were required to undergo a compulsory health screening examination prior to entering university. In total, 28,763 students (12,244 males and 16,519 females), including both graduate and undergraduate levels, completed the health check. Since the mass vaccination program was implemented in July 1984 and conducted in the same month each year, the students were grouped according to their date of birth, with groups stretching from July of a particular year to June of the subsequent year (Table 1). As a result, a total of ten birth cohorts over a period extending from July 1976 to June 1986 were included for analysis in this study. Since the year 2000, an annual survey of serum HsAg status has been conducted for members of the freshman class of Fu-Jen University in September of each year as part of a general youth cohort representative health check-up. All blood samples were transported in a refrigerator to a central laboratory for testing. The serum HsAg level was determined using a commercially available enzyme immunoassay kit (Abbott Laboratories, North Chicago, IL, USA). A regression method was
3 523 Fu-Hsiung Su, et al Forecasting HV rate at a college in Taiwan Table 1. The HsAg Carrier Rate for Taiwanese University Students orn between July 1976 and June 1986 irth HbsAg (+) status in tested population Year of birth cohort Male % (N) 95% CI Female % (N) 95% CI All % (N) 95% CI p-value / / % (55) 12.8~ % (37) 8.5~ % (92) 11.9~ / / % (51) 9.7~ % (31) 5.5~ % (82) 8.5~ / / % (64) 9.6~ % (59) 8.0~ % (123) 9.6~ / / % (84) 8.6~ % (69) 6.9~ % (153) 8.4~ / / % (130) 8.7~ % (114) 7.0~ % (244) 8.3~ / / % (197) 8.4~ % (175) 5.5~ % (372) 7.0~ / / % (171) 7.4~ % (173) 5.1~ % (344) 6.3~ / / % (101) 4.4~ % (133) 4.1~ % (234) 4.5~ / / % (85) 3.7~ % (79) 2.4~ % (164) 3.1~ / / % (29) 1.4~ % (49) 1.7~ % (78) 1.8~ Total 28,763 students 7.9% (967) 7.4~ % (919) 5.3~ % (1886) 6.3~6.9 applied to derived serum HsAg data in order to evaluate any trends displayed in the rate of detected Hs Ag positivity. Comparisons of HsAg carrier rates by gender were performed by means of the Z test. Any difference between data sets was considered significant if the probability of difference was less than A time series statistical method was applied to predict trends in HV infection carrier rates in our sample population. Initially, HsAg carrier rate trends among study participants were interpreted as a non-stationary time series. However, the data were also transformed to constitute a stationary time series by simple differencing. In the mathematical model, {x 1 } was denoted as the HsAg carrier time series. The simple differencing of {x 1 } was denoted by x 1 where x 1 = x 1 x t-1. Thus, subsequent to performing model-building and modelsearching procedures, the ARIMA(2,1,0) model as described by Shumway RH and colleagues was selected as best fitting the data elicited by the study. (11) RESULTS The data showed overall prevalence of HsAg positivity among the students was 6.6% (95% CI: ) [7.9% for males (95% CI: ) and 5.6% (95% CI: ) for females]. There was a significant trend (p < 0.001) toward a decreasing HsAg carrier rate among students at the study university from 14.6% (95% CI: ) to 2.3% (95% CI: ) over the ten-year study period (Table 1). For male students, the HsAg carrier rate declined from 16.8% (95% CI: ) in 1976 to 2.2% (95% CI: ) in 1985; the corresponding figures for females declined from 12.2% (95% CI: ) to 2.4% (95% CI: ), respectively. The reduction was more obvious among male students (Fig. 1). The HsAg carrier rate for male students was significantly greater than that of the female students in the 1977 cohort (p = 0.035), the 1981 cohort (p < 0.001), the 1982 cohort (p < 0.001) and the 1984 cohort (p < 0.001) (Table 1). With the application of the time series method, the ARIMA(2,1,0) model could be rewritten as X t = 1.5X t X t Xt-3 + W t where X t denoted the data value at time t and W t denoted random white noise. Applying this model to predicting trends in the prevalence of HsAg carrier status for this student population (Fig. 2), assuming that there were no interfering factors and that any trend was continuous, the positivity rate for HsAg among students was projected to approach zero for the 1987 cohort, a group comprising students born between 07/01/1987 and 06/30/1988 and expected to enrol in the university in 2006 (Fig. 3). A specific regression method was also applied to evaluate any trend in the HsAg positivity rate with respect to time. Here, Y i denoted the HsAg
4 Fu-Hsiung Su, et al Forecasting HV rate at a college in Taiwan 524 positivity rate and Xi denoted the year. The result showed that a simple linear regression line HsAg positive rate (%) irth cohort (year) male female total Fig. 1 The HsAg carrier rate for Taiwanese university students born between July 1976 and June Rate of HsAg carrier (%) ARIMA(2,1,0) predicted lack line: Actual data plotted line Dot line: ARIMA model predicted trend Fig. 2 The trend in HsAg carrier rates for this student population. Yi = Xi could be fitted to the data. The regression coefficient associated with Xi proved to be negative, indicating that the HsAg positivity rate was declining with time over the test period (Table 2). DISCUSSION From our observations, there appeared to be an abrupt decline in HsAg carrier incidence from the 1976 cohort (14.6%) to the 1977 cohort (10.7%). Subsequently, a steady decline in the HsAg carrier rate from the 1977 cohort to the 1984 cohort was observed. The students in these cohorts as much as seven years old at the time the HV mass-vaccination program commenced. This finding is consistent with a previous study, which looked at children born up to 6 years before the start of the program. (10) Since vertical transmission (the perinatal route) was not modified for these students, the significant reduction in H infection between the 1977 and the 1983 cohorts could be due to a decline in horizontal Rate of HsAg carrier (%) ARIMA(2,1,0) forecast lack line: Actual forecasting line Dot line: Upper and lower forecasting limit Cohortl987:Date of birth (07/01/ /30/1988); Cohortl989:(07/01/ /30/1990);Cohortl990:(07/01/ /30/1991) Fig. 3 Forecasting the trend in HsAg carrier rates for this student population. Table 2. Regression Model of HsAg Carrier Rate for Taiwanese University Freshmen orn between July 1976 and June 1986 Unstandardized Standardized Model coefficients coefficients t Significance Standard error eta 1 (Constant) Year of the research 1.225E Dependent Variable: proportion (percentage) of population that is HsAg (+)
5 525 Fu-Hsiung Su, et al Forecasting HV rate at a college in Taiwan transmission of the virus. (12) We postulate that the obvious decline in the HsAg carrier rate between the 1977 cohort and the 1983 cohort, particularly between the 1981 and 1983 cohorts, might reflect the impact of subsequent catch-up programs, e.g. in the period between 1987 and 1991 (children born between 1981 and 1991 had access to the self-pay preschool program) and the free-of-charge vaccination program for children under seven starting in At the commencement of the national hepatitis- vaccination program in 1984, the completion rate for the total 4-dose HV vaccine was 81.6% for the infants of HV carrier mothers and 9.5% for all newborns. (13) In other words, some carrier mothers were not screened and some newborns of carrier mothers were not vaccinated. Furthermore, unvaccinated children born to non-carrier mothers still exhibited a chance of acquiring HV infection in early childhood from older carriers. (10) Hence the decline of the HsAg positivity rate noted between the 1984 and 1985 cohorts should not only be attributed to the vertical (perinatal) effect of the mass vaccination program; consideration should also be given to the possible horizontal effect of the program as a cause for the decline. Our observations suggest the HV mass-vaccination program successfully reduced horizontal transmission to older children up to age 7, in addition to contributing to the reduction in transmission of hepatitis among children of the same age. (6) Some previous studies have reported the blocking of both vertical and horizontal HV transmission. (6,10) We likewise conclude that twenty years subsequent to the commencement of Taiwan s mass HV vaccination program, the program s effect of reducing horizontal and vertical transmission of HV is still evident, thus the relative efficacy of the vaccination program would appear to have persisted for nearly twenty years. Similar to results of previous studies, (3-5,10,14) our study has revealed that the HsAg carrier rate was higher among males than females. Furthermore, it has been reported that males were more likely to become HsAg carriers following infection than their female counterparts. (3,10,14) Fang JW and his colleagues have suggested that girls responded with a higher anti-hs titre compared with boys after receiving the HV vaccine. (15) As infants and throughout early childhood, male toddlers are typically reported to be more active than their female counterparts and, thus may experience a greater number of opportunities for unwitting parenteral exposure than would appear to be the case for agematched female individuals. (16) These findings have demonstrated that universal vaccination can be used to control vertical and horizontal transmissions of HV infection and the sequelae of chronic HV infection. Given that the chronic HV infection rate has declined in the years following the implementation of Taiwan s mass HV vaccination program, we wished to predict the approximate stage at which HV infection can be virtually eradicated or reduced to a minimal level. The result of time-series analysis indicates that the HV carrier rate will approach zero for the 1987 cohort (students born after 07/01/1987), should the current declining trend in HV carrier rates continue unchanged. Lu SN and colleagues reported the prevalence of HsAg decreased from 12.5% in 1984 to 5.4% in 1991 in one rural township in central Taiwan. (17) In a small district of the Taipei metropolitan area, the HsAg prevalence decreased from 7.3% in surveys done in , to 2% in (18) It is clear that the prevalence of HsAg in rural areas was much higher than urban areas. (17) In 1998, the Department of Health in Taiwan also forecast that if the HV vaccination coverage rate of 90% of all newborns can be maintained, by the year 2010 the carrier rate in Taiwan could be expected to decline to < 0.1%. (19) However, we predicted the carrier rate of HsAg positivity among our student population would decline to a minimal level by the year The discrepancy between our findings and the data presented by the Department of Health might be due to the fact that the majority of our student population was from the greater Taipei metropolitan area and from more affluent families, which means that they likely had easier access to health resources than the general population. Another limitation of the present study is that this mathematical model does not take into account the subsequent catch-up programs and decline of vaccine induced immune memory. Some investigators have pointed out that the possible progressive decline of serum anti-h levels for previously vaccinated individuals over the period following vaccination may be associated with increased likelihood of the developing new H infections over
6 Fu-Hsiung Su, et al Forecasting HV rate at a college in Taiwan 526 time. (20-22) McMahon J and colleagues also suggest that the decline of vaccine-induced memory was greatest for the group aged 0-4 years as compared with other age groups. (23) As a consequence, our results may underestimate the actual HsAg carrier rate in the general population of young adults. Nevertheless, given the results of previous studies 5-, 10- and 16-years post mass vaccination, (6,8-10) using a time-series mathematical model, our data show a continual decrease in the rate of chronic HV infection twenty years subsequent to mass HV vaccination. In addition, it is often suggested that HV infection is the primary aetiology of hepatocellular carcinoma among individuals from many countries, including Taiwan. Therefore, one could say that this study suggests that this mass vaccination program in Taiwan is, to the best of our knowledge, the first occasion where a vaccine may actually prevent a certain type of human cancer. (24) This study confirms the efficacy of a mass HV vaccination program and that the impact of such vaccination remains for at least 20 years subsequent to vaccination. The results suggest that HV vaccination (in Taiwan) not only reduced the perinatal and horizontal transmission of HV among children born after the program commenced, but that such vaccination might also reduce the risk of horizontal transmission of HV to children born up to seven years prior to the commencement of the program. We also predict that the HV infection rate can be reduced to a rather minimal level in 21 years (the 1987 birth cohort expected to enrol in 2006) following the implementation of an universal HV vaccination program among the student population. Clearly, comprehensive, universal HV vaccination programs should be launched in a number of other countries, especially for those for which this virus and associated infections are endemic. REFERENCES 1. Kane MA, Clement J, Hu D. Hepatitis. In: Jamison DT, Mosley WH, Measham AR, obadilla J, eds. Disease Control Priorities in Developing Countries. 1st ed. New York: Oxford University Press, 1993: Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis and C virus infections: a global perspective. Vaccine 1999;17: Chen DS, Sung JL. Hepatitis virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol 1978;25: Wu JS, Chen CH, Chiang YH, Lee YC, Lee MH, Ko YC, Hu HT. Hepatitis virus infection in Taiwan with reference to anti-hc virus HsAg and anti-hs. J Formosan Med Assoc 1980;79: Sung JL, Chen DS, Lai MY, Yu JY, Wang TH, Wang CY, Lee CY, Chen SH, Ko TM. Epidemiological study of hepatitis virus infection in Taiwan. Chin J Gastroenterol 1984;1: Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS. Seroepidemiology of hepatitis virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276: Hsu HM, Lu CF, Lee SC, Lin SR, Chen DS. Seroepidemiologic survey for hepatitis virus infection in Taiwan: the effect of hepatitis mass immunization. J Infect Dis 1999;179: Tsen YJ, Chang MY, Hsu HY, Lee CY, Sung JL, Chen DS. Seroprevalence of hepatitis infection in children in Taipei, 1989: five years after a mass hepatitis vaccination program. J Med Virol 1991;34: Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336: Lin HH, Wang LY, Hu CT, Huang SC, Huang LC, Lin SS, Chiang YM, Liu TT, Chen CL. Decline of hepatitis carrier rate in vaccinated and unvaccinated subjects: sixteen years after a newborn vaccination program in Taiwan. J Med Virol 2003;69: Shumway RH, Stoffer DS. Time Series Regression and ARIMA Models. In: Shumway RH, Stoffer DS, eds. Time Series Analysis and Its Applications. 1 st ed. New York: Springer-Verlag, 2000: Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis virus in children. J Pediatr Gastroenterol Nut 1993;16: Wong WCW, Tsang KK. A mass hepatitis vaccination programme in Taiwan: its preparation, results and reasons for uncompleted vaccinations. Vaccine 1994;12: Lin HH, Wu JS, Lu CF, Wong CK. Hepatitis virus infection among aboriginal children in eastern Taiwan. J Formos Med Assoc 1992;91: Fang JW, Lai CL, Chung HT, Wu PC, Lau JY. Female children respond to recombinant hepatitis vaccine with a higher titre than male. J Trop Pediatr 1994;40: Lin HH, Lin SS, Chiang YM, Chiang YM, Wang LY, Huang LC, Huang SC, Liu TT. Trend of hepatitis virus infection in freshmen classes at two high schools in Hualien, Taiwan from 1991 to J Med Virol 2002;67: Lu SN, Chen CH, Chen TM, Lee PL, Wang JH, Tung HD, Hung CH, Lee CM, Changchien CS. Hepatitis virus infection in adolescents in a rural township--15 years sub-
7 527 Fu-Hsiung Su, et al Forecasting HV rate at a college in Taiwan sequent to mass hepatitis vaccination in Taiwan. Vaccine 2006;24: Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, Chen DS. Hepatitis virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis vaccination. Ann Intern Med 2001;135: Department of Health. Public Health in Taiwan, Republic of China. The Executive Yuan 1998;2: Coursaget P, Yvonnet, Chotard J, Sarr M, Vincelot P, N doye R, Diop-Mar I, Chiron JP. Seven-year study of hepatitis vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986;2: Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis vaccine in infants born to hepatitis e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed 1997;77:F Lu CY, Chiang L, Chi WK, Chang MH, Ni YH, Hsu HM, Twu SJ, Su IJ, Huang LM, Lee CY. Waning immunity to plasma-derived hepatitis vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004;40: McMahon J, ruden DL, Petersen KM, ulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis vaccination: results of a 15-year follow up. Ann Intern Med 2005;142: Zuckerman AJ. Prevention of primary liver cancer by immunization. N Engl J Med 1997;336:
8 , Z 16.8% ( ) 2.2% ( ) % 2.4% ( 2006 ) 21 ( 2007;30:521-8) Tel.: (02) ; Fax: (02) ; cdchen@mail.femh.org.tw
Hepatitis B virus (HBV) infection is an important. Brief Communication
Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,
More informationIncomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees
Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Yin-Chu Chien, 1 Chyi-Feng Jan, 2 Chun-Ju Chiang, 3 Hsu-Sung
More informationEstimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants
ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1
More informationB C ALT B C B B C
2006 17 276-290 520 ( Hepatitis surface antigen, HsAg ) ( Anti-hepatitis virus antibody anti-hv ) ( alanine transaminase ) 2004 4 11 31 533 216 (n=56702; / : 17551/39151) HsAg anti-hv 40 IU/L (standardized
More informationHEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN
UNIVERSAL HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN MEI-HWEI CHANG, M.D., CHIEN-JEN CHEN, SC.D., MEI-SHU LAI, M.D., HSU-MEI HSU, M.P.H., TZEE-CHUNG WU,
More informationHepatitis B surface antigen HBsAg Hepatitis B e antigen HBeAg 1) B
292 14 4 B Effects of the Vaccination Against Hepatitis B Virus for All Infants in Taiwan Chang-Kuen Tien, Nobutaka Kurihara, Hiroyuki Yanagisawa and Osamu Wada (Hygiene and Preventive Medicine, Saitama
More informationUniversal hepatitis B (HB) immunization has
Determination of Immune Memory to Hepatitis B Vaccination Through Early Booster Response in College Students Chyi-Feng Jan, 1,2 Kuo-Chin Huang, 1 Yin-Chu Chien, 3 Donald E. Greydanus, 2 H. Dele Davies,
More informationThe Hepatitis B Vaccine: What Went Wrong?
The Hepatitis B Vaccine: What Went Wrong? By F. Edward Yazbak, MD, FAAP On Dec. 23, 2005, the Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (1) in which
More informationAlthough substantial progress has been made in
VIRAL HEPATITIS Waning Immunity to Plasma-Derived Hepatitis B Vaccine and the Need for Boosters 15 Years After Neonatal Vaccination Chun-Yi Lu, 1 Bor-Luen Chiang, 1,2 Wei-Kuang Chi, 3 Mei-Hwei Chang, 1
More informationChanging Prevalence of Anti-Hepatitis A Virus in Adolescents in A Rural Township in Taiwan
Original Article 321 Changing Prevalence of Anti-Hepatitis A Virus in Adolescents in A Rural Township in Taiwan Jing-Yi Chen 1,2,5, MD; Jui-Chin Chiang 1,2,6, MD; Sheng-Nan Lu 2,3,4, MD, MPH, PhD; Shu-Fen
More informationTwo Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies
GASTROENTEROLOGY 2007;132:1287 1293 Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies YEN HSUAN NI,* LI MIN HUANG,* MEI HWEI CHANG,* CHUNG JEN YEN,
More informationHepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan
Original Article 137 Hepatitis Delta Virus and GBV-C Infection in Two Neighboring Hepatitis B Virus and Hepatitis C Virus Endemic Villages in Taiwan Chang-Jung Chang 1, MD; Jui-Chin Chiang 1,2,6, MD; Sheng-Nan
More informationDecreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
ARTICLE Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study Mei-Hwei Chang, San-Lin You, Chien-Jen Chen, Chun-Jen Liu, Chuan-Mo Lee, Shi-Ming Lin, Heng-Cheng
More informationAge-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan,
Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan, 1976 2005 LONG-TENG LEE, HSIAO-YUAN HUANG, KUO-CHIN HUANG, CHING-YU CHEN, AND WEN-CHUNG LEE PURPOSE: Hepatocellular carcinoma
More informationHepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis
Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic
More informationMore than 2 billion people in the world are infected
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:941 945 18-Year Follow-up Study of a Prospective Randomized Trial of Hepatitis B Vaccinations Without Booster Doses in Children MAN FUNG YUEN,* WEI LING
More informationHumoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster Years after Neonatal Immunization
MAJOR ARTICLE Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15 18 Years after Neonatal Immunization Chun-Yi Lu, 1 Yen-Hsuan Ni, 1 Bor-Luen Chiang, 1 Pei-Jer Chen, 2 Mei-Hwei Chang,
More informationS ince effective vaccines against hepatitis B became
1499 LIVER Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan H-Y Hsu, M-H Chang, Y-H Ni, H-L Chen... See end of article for authors
More information62 La Revue de Santé de la Méditerranée orientale, Vol. 11, N o 1/2, 2005
62 La Revue de Santé de la Méditerranée orientale, Vol. 11, N o 1/2, 2005 Rate of hepatitis B seropositivity following mass vaccination in the Islamic Republic of Iran M-R. Zali, 1 K. Mohammad, 2 A-A.
More informationAN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS
AN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS Thosporn Vimolket 1 and Yong Poovorawan 2 1 Department
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationDownloaded from:
Whittle, H; Jaffar, S; Wansbrough, M; Mendy, M; Dumpis, U; Collinson, A; Hall, A (22) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ, 325
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationObservational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children Hilton Whittle, Shabbar Jaffar, Michael Wansbrough, Maimuna Mendy, Uga Dumpis, Andrew Collinson,
More informationuniversal vaccination
Vol. 21No. 2149 8 HB B universal vaccination Blumberg HBs B 40 B HBV HBV HBV HBs WHO 1992 HBV B HB universal vaccination 1997 HB universal vaccination HBV high risk HBV universal vaccination B HBV universal
More informationCURRICULUM VITAE China Medical College, College of Medicine, Taichung, Taiwan, R.O.C.
CURRICULUM VITAE NAME: Huang, Chung-Ming OFFICE ADDRESS: China Medical University Hospital, No. 2, Yuh-Der Road, Taichung, Taiwan, R.O.C., 北 路 2 EDUCATION: 1978-1985 China Medical College, College of Medicine,
More informationHepatitis B virus (HBV) is a significant cause of
Secular Trend of the Viral Genotype Distribution in Children With Chronic Hepatitis B Virus Infection After Universal Infant Immunization Wan-Hsin Wen, 1,6,7 Huey-Ling Chen, 1,2 Yen-Hsuan Ni, 1 Hong-Yuan
More informationCURRICULUM VITAE Name : Gender : Birth Place : address : Contact Tel : Education: Training and Working Experiences: Awards:
Name : Szu-Hua Pan Gender : Female Birth Place : Taipei, Taiwan E-mail address : shpan@ntu.edu.tw Contact Tel : 02-23123456 ext. 88661 CURRICULUM VITAE Education: 1991~1994 B.S., Department of Nutrition
More informationDepartment of Public Health, Taipei Medical University, Taipei City, Taiwan
Page 1 of 30 1 TITLE PAGE Title: Chronic hepatitis B infection in adolescents who had received primary infantile vaccination. Authors and affiliations Tzu-Wei Wu 1,*, Hans Hsienhong Lin 2,3*, Li-Yu Wang
More informationChristy Pu Institutes Degree Department Period National Yang-Ming University (Taiwan)
Christy Pu cypu@ym.edu.tw Degree Institutes Degree Department Period National Yang-Ming University (Taiwan) PhD Public Health 09/2005~06/2008 University of Oxford (UK) MSc Economics 08/2002~07/2003 University
More informationHepatitis B virus (HBV) infection is a global
VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung
More informationAge-Period-Cohort Analysis of Liver Cancer Mortality in Korea
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.18.8589 Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea RESEARCH ARTICLE Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea Jihwan Park
More informationUnderstanding of Senile Dementia by Children and Adolescents: Why Grandma Can t Remember Me?
138 Understanding of Senile Dementia by Children and Adolescents: Why Grandma Can t Remember Me? Jong-Ling Fuh 1, Shuu-Jiun Wang 1, and Kai-Di Juang 2 Abstract- Background: The present study sought to
More informationRESUME Sep National Medical License, Taiwan Oct Board of Interal Medicine, Taiwan Aug Board of Cardiology, Internal Medicine, Taiwan
RESUME Ye-Hsu Lu, M.D. Office Address: No.100, Ziyou 1st Rd., Sanmin Dist., Kaohsiung City 80708, Taiwan TEL: +886-7-3121101 ext. 7741 (Office), +886-918867017 (Cell) FAX: +886-7-3234845 E-mail: yehslu@gmail.com
More information2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities ( 2017:27: (07)
116 2013 1 2 2 1 3 4 5 6 7 8 9 2 10 11 2 12 13 14 15 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 2025 2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis B virus (HBV) infection can cause
Prevention of Hepatitis B Mei-Hwei Chang 1,2 and Ding-Shinn Chen 2,3,4 1 Department of Pediatrics, National Taiwan University Hospital, Taipei 10016, Taiwan 2 Hepatitis Research Center, National Taiwan
More informationChing-Wen Wang, Li-Chieh Wang, Mei-Hwei Chang,* Yen-Hsuan Ni, Huey-Ling Chen, Hong-Yuan Hsu, and Ding-Shin Chen
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Dec. 2005, p. 1442 1447 Vol. 12, No. 12 1071-412X/05/$08.00 0 doi:10.1128/cdli.12.12.1442 1447.2005 Copyright 2005, American Society for Microbiology. All
More informationIncidence and Risk of Alcohol Use Disorders by Age, Gender and Poverty Status: A Population-Based-10 Year Follow-Up Study
Incidence and Risk of Alcohol Use Disorders by Age, Gender and Poverty Status: A Population-Based-10 Year Chun-Te Lee 1,2, Chiu-Yueh Hsiao 3, Yi-Chyan Chen 4,5, Oswald Ndi Nfor 6, Jing-Yang Huang 6, Lee
More informationJose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas
Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence
More informationEpidemiology of Hepatitis B in sub-saharan Africa. 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur
Epidemiology of Hepatitis B in sub-saharan Africa 7 February 2018 Yusuke Shimakawa, MD, PhD Institut Pasteur From the Big Three to the Big Four 1600000 Number of deaths/year 1400000 HAV + HEV 1200000 1000000
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationThe Diabetes Epidemic in Korea
Review Article Endocrinol Metab 2016;31:349-33 http://dx.doi.org/.3803/enm.2016.31.3.349 pissn 2093-96X eissn 2093-978 The Diabetes Epidemic in Korea Junghyun Noh Department of Internal Medicine, Inje
More informationSEROLOGICAL SURVEY OF VIRAL HEPATITIS A, B, AND C AT THAI CENTRAL REGION AND BANGKOK: A POPULATION BASE STUDY
SEROLOGICAL SURVEY OF VIRAL HEPATITIS A, B, AND C AT THAI CENTRAL REGION AND BANGKOK: A POPULATION BASE STUDY Winai Ratanasuwan 1, Areeua Sonji 1, Surapee Tiengrim 2, Wichai Techasathit 1 and Surapol Suwanagool
More informationHepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia
Hepatitis B from targeted screening and immunisation of migrant mothers to universal immunisation in Australia Tilman Ruff Nossal Institute for Global Health, University of Melbourne Consultant: Australian
More informationGlobal Epidemiology and Prevention of Hepatitis B
Global Epidemiology and Prevention of Hepatitis B Dr. Steven Wiersma WHO Geneva Strengthening immunisation systems and introduction of hepatitis B vaccine in Central and Eastern Europe and the Newly Independent
More informationMathematical Model of Hepatitis B in. the Bosomtwe District of Ashanti Region, Ghana
Applied Mathematical Sciences, Vol. 8, 2014, no. 67, 3343-3358 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/ams.2014.44263 Mathematical Model of Hepatitis B in the Bosomtwe District of Ashanti
More informationLong term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers
Archives of Disease in Childhood 1997;77:F47 F51 F47 Viral Hepatitis Research Unit Chulalongkorn University Hospital, Bangkok, Thailand Y Poovorawan Department of Paediatrics S Sanpavat S Chumdermpadetsuk
More informationVaccine 28 (2010) Contents lists available at ScienceDirect. Vaccine. journal homepage:
Vaccine 28 (2010) 730 736 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Persistence of antibodies and immune memory to hepatitis B vaccine 20 years
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHepatitis B virus (HBV) infection is a global. Chronic Hepatitis B Infection in Adolescents Who Received Primary Infantile Vaccination
Chronic Hepatitis B Infection in Adolescents Who Received Primary Infantile Vaccination Tzu-Wei Wu, 1 * Hans Hsienhong Lin, 2,3 * and Li-Yu Wang 1,4 Hepatitis B virus (HBV) infection is a global health
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationHEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium
HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Anchorage, Alaska USA Goals of My Lecture Highlight the
More informationPROFESSIONAL EXPERIENCE
EDUCATION Doctor of Philosophy, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University Master of Science, Division of Organic Chemistry, Chemistry, National Taiwan
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationHepatitis B: A Silent Epidemic for Asian-Americans
Fiona Hinze HumBio 122M June 6, 2012 Hepatitis B: A Silent Epidemic for Asian-Americans The Issue Hepatitis B is a viral disease that causes 80% of liver cancers (hepatocellular carcinoma). Hepatitis B
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationChanges in the seroprevalence of IgG anti-hepatitis A virus between 2001 and 2013: experience at a single center in Korea
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 214;2:162-167 Changes in the seroprevalence of IgG anti-hepatitis A virus between 21 and 213: experience at a single center
More informationEVALUATION OF THE SCHOOL-BASED HEPATITIS B VACCINATION PROGRAMME IN CATALONIA (SPAIN)
EVALUATION OF THE SCHOOL-BASED HEPATITIS B VACCINATION PROGRAMME IN CATALONIA (SPAIN) Prof. L. Salleras Department of Public Health University of Barcelona Hospital Clínic Barcelona Hepatitis B vaccine:
More informationEpidemiology and Natural History of Hepatitis B in Children
Epidemiology and Natural History of Hepatitis B in Children Szu-Ta Chen and Mei-Hwei Chang Key Concepts Patients in countries with high HBV endemicity tend to have perinatal transmission of hepatitis B,
More informationhepatitis B virus B 15% 25 HBsAg B HBV HBsAg 15% 20% HBV HBV 90% 16 HIV HBV
hepatitis virus HV 20 15% 25 20 30 HV HsAg 3 5 100 HV 15% 20% HV HsAg HV HV HV 90% 16 5% HV 10 59 http://www.aids-care.org.tw HV CD8 73% 98% HV 90% HV HsAg 6 10% HsAg 0.5% 1% HV HV HV HV HCV TNF- TNF-
More informationA Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea
ORIGINAL ARTICLE Pediatrics https://doi.org/10.3346/jkms.2017.32.5.810 J Korean Med Sci 2017; 32: 810-816 A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program
More informationThe Epidemiologic Transition of Diabetes Mellitus in Taiwan: Implications for Reversal of Female Preponderance from a National Cohort
18 The Open Diabetes Journal, 29, 2, 18-23 Open Access The Epidemiologic Transition of Diabetes Mellitus in Taiwan: Implications for Reversal of Female Preponderance from a National Cohort Chin-Hsiao Tseng
More informationHorizontal Transmission of Hepatitis B Virus from Siblings and Intramuscular Injection among Preschool Children in a Familial Cohort
American Journal of Epidemiology Vol 133, No. 10 Copyright ffl 1991 by the Johns Hopkins University School of Hygiene and Public Health Printed in U S.A. All rights reserved Horizontal Transmission of
More informationLUAN-YIN CHANG. Division of Pediatric Infectious Diseases, Department of Pediatrics, National Taiwan University Hospital Attending Physician
LUAN-YIN CHANG Institution: Title: Tel No.: Fax No.: E-mail: Address: Division of Pediatric Infectious Diseases, Department of Pediatrics, National Taiwan University Hospital Attending Physician lychang@ntu.edu.tw
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationJournal of Chinese Medicine. Vol.20, No.1, Vol.20, No.3,
163 Journal of Chinese Medicine Vol.20, No.1,2 1-96 Vol.20, No.3,4 97-162 ~ - 145 45-135 21 117 79-19 137-135 ~ - 137 65 87-65 - 145-65 - 153-79 - 153-87 47-137 - 65-87 - 47-145 - 145-47 - 19 164 153 HT7
More informationBalance Sheets 1. CHILD HEALTH... PAGE NUTRITION... PAGE WOMEN S HEALTH... PAGE WATER AND ENVIRONMENTAL SANITATION...
Balance Sheets A summary of the goals, gains and unfinished business of the 1990-2000 decade as included in the Report of the Secretary-General, 'We the Children: End-decade review of the follow-up to
More informationHepatitis B Does Not Explain Male-Biased Sex Ratios in China
Hepatitis B Does Not Explain Male-Biased Sex Ratios in China Emily Oster University of Chicago and NBER Gang Chen Hepatitis B Foundation Wenyao Lin Haimen CDC Xinsen Yu Haimen CDC Draft: April 10, 2008
More informationORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university
Malaysian J Pathol 2018; 40(3) : 295 302 ORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university Siti Norlia OTHMAN, Zetti ZAINOL
More informationAre booster immunisations needed for lifelong hepatitis B immunity?
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support
More informationWei-Chung Cheng ( 鄭維中 )
Wei-Chung Cheng ( 鄭維中 ) Graduate Institute of Biomedical Scienses China Medical University 8F, No. 6, Hsueh-Shih Road, Taichung 404, Taiwan TaiChung 404, Taiwan E-mail: wccheng@mail.cmu.edu.tw Office :
More informationCorrelation between the levels of anti- A/B IgM/IgG antibodies and cord blood bilirubin levels in haemolytic disease of the new-born
Original article Correlation between the levels anti- A/B IgM/IgG antibodies and cord blood bilirubin levels in haemolytic disease the new-born C HEMACHANDRIKA 1* TK SHAANTHI GUNASINGH 2 1Pressor & Head,
More information162 Biomed Environ Sci, 2014; 27(3):
162 Biomed Environ Sci, 2014; 27(3): 162-168 Original Article Impact of Cardiovascular Disease Deaths on Life Expectancy in Chinese Population * FAN Jie, LI Guo Qi, LIU Jing, WANG Wei, WANG Miao, QI Yue,
More information17th EHFG Electing Health The Europe We Want!
01 03 October 2014 17th EHFG Electing Health The Europe We Want! For more information about the final programme, speakers or the EHFG conference please contact us directly! Follow us on our social media
More informationAsian-Oceanian Journal of Pediatrics and Child Health JAPANESE PEDIATRIC BOARD CERTIFICATION: HISTORY AND FUTURE PERSPECTIVES
Asian-Oceanian Journal of Pediatrics and Child Health Volume One December 2002 Number Two JAPANESE PEDIATRIC BOARD CERTIFICATION: HISTORY AND FUTURE PERSPECTIVES Nobutake Matsuo, M.D. (1), John Ichiro
More informationHBV in New Zealand Community HBV screening to long-term follow-up
HBsAg+ icteric hepatitis (n) % anti-hbcore+ 26/9/214 HBV in New Zealand Community HBV screening to long-term follow-up John Hornell, CEO, A registered charitable trust whose mission is: To improve health
More informationCrucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C
Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Prakash C Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationSummary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background:
Prepared by: TV Murphy, MD, September 16, 2016 Summary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background: The primary
More informationNHS public health functions agreement Service specification No.1 Neonatal hepatitis B immunisation programme
NHS public health functions agreement 2017-18 Service specification No.1 Neonatal hepatitis B immunisation programme NHS public health functions agreement 2017-18 Service specification No.1Neonatal hepatitis
More informationHepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. Vana Papaevangelou (Greece) National and Kapodistrian University of Athens Chang SemFNM
More informationHepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity
1 Hepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity Dr. Salwa Ibrahim, MD MRCP Assistant Professor of Nephrology Cairo University, Egypt Patients on hemodialysis therapy
More informationTreatment of Non-cirrhotic Incarcerated Genotype 6 Chronic Hepatitis C Injection Drug Users, Compared with Genotype 1
DOI 10.6314/JIMT.201812_29(6).06 2018 29 393-400 Treatment of Non-cirrhotic Incarcerated Genotype 6 Chronic Hepatitis C Injection Drug Users, Compared with Genotype 1 Lian-Feng Lin 1,3, Yi-Chun Chan 1,
More informationChia-Lin Li, Ph.D. Professor Department of Health Care Management College of Management Chang Gung University
Chia-Lin Li, Ph.D. Professor Department of Health Care Management College of Management Chang Gung University clli@mail.cgu.edu.tw Academic Background Ph.D. Institute of Public Health, National Yang-Ming
More informationSEROLOGIC MARKERS OF EPSTEIN BARR VIRUS INFECTION AND NASOPHARYNGEAL CARCINOMA
SEROLOGIC MARKERS OF EPSTEIN BARR VIRUS INFECTION AND NASOPHARYNGEAL CARCINOMA SEROLOGIC MARKERS OF EPSTEIN BARR VIRUS INFECTION AND NASOPHARYNGEAL CARCINOMA IN TAIWANESE MEN YIN-CHU CHIEN, M.SC., JEN-YANG
More informationGlobal Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J
97 Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J Chun-Jen Liu, MD, PhD 1,2,3 Jia-Horng Kao, MD, PhD 1,2,3,4 1 Graduate Institute of Clinical
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationSafety and health training model It is expected that better recognition of hazards can reduce risks to workers. Course depth and suitable teaching met
Y.J. Hong, Y.H. Lin, H.H. Pai, et al DEVELOPING A SAFETY AND HEALTH TRAINING MODEL FOR PETROCHEMICAL WORKERS Yu-Jue Hong, Ya-Hsuan Lin, Hsiu-Hua Pai, 1 Yung-Chang Lai, 2 and I-Nong Lee 3 Institute of Public
More informationIncrease Hepatitis B Screening and Vaccinations
17 Increase Hepatitis B Screening and Vaccinations Situation Viral hepatitis is considered to be the most common contagious disease in Japan. Of the estimated three million patients and carriers of viral
More informationHepatocellular carcinoma (HCC) is still one of the. Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan
HEPATOBILIARY MALIGNANCIES Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan Yen-Po Yeh, 1 Tsung-Hui Hu, 2 Po-Yuan Cho, 3 Hsiu-Hsi Chen, 4 Amy Ming-Fang Yen,
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 1.1111/j.1469-691.24.19.x Chronological evolution of,, and neutralisation antibodies after infection with SARS-associated coronavirus P.-R. Hsueh 1,2, L.-M. Huang 3, P.-J. Chen 2, C.-L.
More information26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges
Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids
More informationPublication list. 1. Chou AH, Chen SY, Yeh TH, Weng YS, Wang HL*. HDAC inhibitor sodium
Publication list 1. Chou AH, Chen SY, Yeh TH, Weng YS, Wang HL*. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
More informationEpatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationCurrent status and strategies for hepatitis B control in Korea
pissn 2287-2728 eissn 2287-285X Review Clinical and Molecular Hepatology 2017;23:205-211 Current status and strategies for hepatitis B control in Korea Eun Ju Cho 1, Sung Eun Kim 2, Ki Tae Suk 3, Jihyun
More informationEPIDEMIOLOGIC CHARACTERISTICS OF HEPATITIS A VIRUS INFECTIONS IN GREECE 1
AMERICAN JOURNAL OF EPIDEMIOLOGY Vol. 112, 4 Copyright 1980 by The Johns Hopkins University School of Hygiene and Public Health Printed in U.S-A. All rights reserved EPIDEMIOLOGIC CHARACTERISTICS OF HEPATITIS
More information